Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 10301 - 10350By Sending Tests by Mail, Researchers Boost Colorectal Cancer Screening Rates Among Medicaid Patients
Mailing colorectal cancer screening tests to patients insured by Medicaid increased screening rates for this population, reported researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. In collaboration with the Mecklenburg County Health Department in...
Study Evaluates Effects of Affordable Care Act on Young Women With Gynecologic Cancer
The gains in insurance coverage with the Patient Protection and Affordable Care Act (ACA) have already translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits. That’s the conclusion of a new ...
Meta-Analysis of Patients With Early Kidney Cancer Treated With Robotic Partial Nephrectomy
For patients with early kidney cancer, surgically removing a portion of the kidney instead of the whole organ is often a preferred treatment, because the procedure can effectively remove tumors while preserving kidney function. But when it comes to the best surgical approach—robotic,...
Brain Metastases in ROS1-Positive Lung Cancer and Treatment With Crizotinib
A study published by Patil et al in the Journal of Thoracic Oncology explores the occurrence and treatment of brain metastases in stage IV ROS1-positive non–small cell lung cancer. ROS1-Positive Disease vs Other Genetic Mutations Importantly, and in contrast with the findings ...
Phase III TOURMALINE-MM3 Trial of Ixazomib as Maintenance Therapy in Patients With Multiple Myeloma Posttransplant
The randomized, phase III TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral ixazomib (Ninlaro) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) vs placebo. The trial evaluated the effect of ixazomib as a...
NCCN Releases New Guidelines for Patients With AML
The National Comprehensive Cancer Network® (NCCN®) has recently released The NCCN Guidelines for Patients with Acute Myeloid Leukemia (AML), which includes resources for better-informed medical decision-making. The NCCN Guidelines for Patients with AML is endorsed by the Aplastic Anemia and MDS...
NCI and VA Launch NAVIGATE to Boost Veterans’ Access to Cancer Clinical Trials
Veterans with cancer who receive treatment from the U.S. Department of Veterans Affairs (VA) will now have easier access to clinical trials of novel cancer treatments, thanks to an agreement between the VA and the National Cancer Institute (NCI), part of the National Institutes of Health. The NCI...
Study Finds Gender Disparities in Head and Neck Cancer Treatment and Outcomes
An analysis of cancer registry data from a California hospital system showed that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs 46%) and radiation (60% vs 70%) compared to men. Controlling for factors such as age and serious medical conditions, a...
In Case You Missed It: Update on Breast Cancer Research
The ASCO Post presents these brief summaries of important studies in breast cancer, presented at the 2018 ASCO Annual Meeting. Ribociclib Plus Fulvestrant in Metastatic Breast Cancer The benefit of an inhibitor of cyclin-dependent kinase 4/6 (CDK4/6) added to fulvestrant has now been proven to...
In Case You Missed It: Short Takes on Current Cancer Research
It would be impossible to cover all of the important presentations from the 5,000-plus abstracts accepted for the 2018 ASCO Annual Meeting. In addition to our regular meeting coverage of the top news stories, the following highlights focus on novel investigational approaches to therapy for various...
Nivolumab Plus Low-Dose Ipilimumab Approved for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer
On July 11, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal...
Oral Taxane Shows Strong Activity and Good Tolerability in Metastatic Breast Cancer
As first-line treatment for metastatic breast cancer, the oral taxane tesetaxel produced a 45% confirmed response rate and was well tolerated, producing little alopecia or neuropathy, according to Andrew D. Seidman, MD, and colleagues from several cancer centers. Dr. Seidman, of Memorial Sloan...
Expert Point of View: Shannon Westin, MD
Shannon Westin, MD, Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, Houston, served as an ASCO expert for the press briefing and made several comments. “What we’re learning is that among tumors with...
Geographic Differences in End-of-Life Cancer Care
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found differences in this type of cancer care across different parts of the country. The findings, published by Keating et al...
FDA Expands Ribociclib Indication in Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Today, the U.S. Food and Drug Administration (FDA) expanded the indication for ribociclib (Kisqali) in combination with an aromatase inhibitor for premenopausal or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer as initial...
MSI-High Status and Lynch Syndrome Found in Surprising Variety of Cancers
In a study that many consider to be practice-changing, Lynch syndrome, a hereditary cancer predisposition syndrome, was found in many persons who would not ordinarily be suspected of having it.1 The study, which was presented at the 2018 ASCO Annual Meeting, has implications for broader testing...
Expert Point of View: David Graham, MD, FASCO and Richard Schilsky, MD, FACP, FASCO, FSCT
ASCO expert David Graham, MD, FASCO, of the Levine Cancer Institute in Charlotte, North Carolina, was encouraged by the IMpower131 findings. “This is one more example of how immunotherapy is making steady gains against a number of cancers. Immunotherapy has been shown to be effective in other...
Atezolizumab Plus Chemotherapy Extends Survival in Squamous NSCLC Regardless of PD-L1 Level
Patients with advanced squamous non–small cell lung cancer (NSCLC) had a greater benefit from first-line treatment with the combination of atezolizumab (Tecentriq) plus chemotherapy vs chemotherapy alone in the randomized, phase III, IMpower131 clinical trial.1 At the landmark of 12-month...
Expert Point of View: Selma Ugurel, MD
Selma Ugurel, MD, of the Skin Cancer Center Essen at the University of Duisburg-Essen, Germany, discussed the Merkel cell carcinoma presentations at the 2018 ASCO Annual Meeting. “Immunotherapy is of high interest in Merkel cell because of the high immunogenicity of the tumor—viral-induced and...
Immunotherapy in Merkel Cell Carcinoma: ‘Field Has Been Thrown on Its Head’
At the 2018 ASCO Annual Meeting, investigators presented long-term follow-up data for immunotherapy in patients with Merkel cell carcinoma and new data for its use in the neoadjuvant setting. The results drew high interest from attendees and a number of questions were raised following the...
Expert Point of View: Colin D. Weekes, MD, PhD and Manish A. Shah, MD, FASCO
Two pancreatic cancer specialists commented on the PREOPANC-1 study for The ASCO Post: Colin D. Weekes, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, Boston, who had discussed the abstract at the ASCO Annual Meeting, and Manish A. Shah, MD, FASCO, Chief of the Solid Tumor...
Preliminary Data Suggest Neoadjuvant Chemoradiotherapy May Improve Outcomes in Patients With Early Stages of Pancreatic Cancer
For patients with newly diagnosed, potentially resectable pancreatic cancer, neoadjuvant chemoradiotherapy led to better outcomes when compared with immediate surgery followed by chemoradiotherapy in the phase III PREOPANC-1 trial. Approximately 25% fewer deaths occurred among patients in the...
FDA Grants Priority Review to sBLA for Pembrolizumab in Advanced Hepatocellular Carcinoma
The U.S. Food and Drug Administration (FDA) recently accepted and granted priority review for a new supplemental biologics license application (sBLA) seeking approval for pembrolizumab (Keytruda) as a second-line treatment for patients with advanced hepatocellular carcinoma. This sBLA, which is...
Early Study Shows Elasticity of Cancer Cells May Determine Where Pancreatic Cancer Metastases Form
Pancreatic cancer often metastasizes to the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells’ ability to alter their characteristics and shape—as a research team at the...
American Cancer Society Outlines Blueprint for Cancer Control in the 21st Century
The American Cancer Society (ACS) is outlining its vision for cancer control in the decades ahead in a series of articles that began publishing in early July in CA: A Cancer Journal for Clinicians. The series of articles forms the basis of a national cancer control plan, with a blueprint...
FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer
On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient population to include patients with either nonmetastatic CRPC or metastatic CRPC. Enzalutamide was ...
NCI and VA Launch NAVIGATE to Boost Veterans’ Access to Cancer Clinical Trials
Veterans with cancer who receive treatment from the U.S. Department of Veterans Affairs (VA) will now have easier access to clinical trials of novel cancer treatments, thanks to an agreement between the VA and the National Cancer Institute (NCI), part of the National Institutes of Health. The NCI...
Palliative Care Preferences in Male Patients With Cancer
Men with advanced cancer are 30% less likely than women to consider palliative care, according to a University of Rochester Medical Center (URMC) study. Researchers believe the findings reflect social norms about gender roles, as well as widespread messages in the media and society about...
Human Papillomavirus Vaccine in Cutaneous Basaloid Squamous Cell Carcinomas
Squamous cell carcinoma is the second-most-common form of skin cancer. Evidence suggests the human papillomavirus (HPV) plays a role in the development of some types of this skin cancer. Two years ago, a 97-year-old woman whose right leg was covered with squamous cell tumors went to see...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Sharon H. Giordano, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, ASCO has released a clinical practice guideline update on systemic therapy for patients with advanced HER2-positive breast cancer. The guideline update...
Statement by FDA Commissioner on Opioid Access for Patients With Chronic and End-of-Life Pain
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, recently issued the following statement. The opioid epidemic continues to take an emotional, physical, and financial toll on Americans. The FDA is committed to taking every possible step to address the many facets of this...
ESHRE 2018: Large Population Study Does Not Find Causal Link Between Assisted Reproduction and Ovarian Cancer Risk
Following concerns over many years that hormonal stimulation of the ovaries necessary for in vitro fertilization (IVF) may increase the risk of ovarian cancer, a nationwide cohort study from Denmark has now concluded that any perceived increase in risk is actually a statistical bias resulting from...
ESHRE 2018: Early-Stage Research Shows Potential of Artificial Ovary for Fertility Preservation Without the Risk of Reintroducing Malignancy
Important steps in the development of an artificial ovary have been successfully completed. Researchers from the Rigshospitalet in Copenhagen, Denmark, reported that they have—for the first time—isolated and grown human follicles to a point of biofunctionality on a bioengineered ovarian ...
FDA Approves Nivolumab Plus Low-Dose Ipilimumab for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer
Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR)...
A. Oliver Sartor, MD, on Issues in Immunotherapy
A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage disease about the knowns, unknowns, risks, and toxicities of using a therapy outside the context of a clinical trial setting. The ...
Owen A. O’Connor, MD, PhD, on Issues in Immunotherapy
Owen A. O'Connor, MD, PhD, of Columbia University Medical Center, shares his perspective on immunotherapy for patients with late-stage cancer in the context of a clinical trial setting and recent Right-to-Try legislation. The content in this post has not been reviewed by the American Society of...
Andrew D. Seidman, MD, on Embracing Computer-Assisted Decision-Making
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discusses the benefits of decision support tools, especially for the oncologist who treats a variety of cancers in his or her practice. The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. ...
Allen S. Lichter, MD, and Mark J. Ratain, MD, on Better Dosing, Lower Cost: Improving Cancer Care and Value
Allen S. Lichter, MD, Board Chair of the Value in Cancer Care Consortium, and Mark J. Ratain, MD, of the University of Chicago, discuss the benefits—and challenges—of lowering dosages in the face of market forces. The content in this post has not been reviewed by the American Society of Clinical...
FDA Accepts sBLA for Pembrolizumab in Combination With Chemotherapy as First-Line Treatment for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) in combination with carboplatin/paclitaxel or nab-paclitaxel (Abraxane) as a first-line treatment for metastatic squamous non–small cell lung...
Study Finds Inherited Gene Variants in 10% of Patients With Pancreatic Cancer
A large study of pancreatic cancer patients found that almost 10% harbored inherited genetic variations or mutations that may have increased their susceptibility to the disease. At the same time, some of these mutations were associated with more favorable responses to certain chemotherapy agents,...
FDA Grants Orphan Drug Designation to CPI-613 for Treatment of Burkitt Lymphoma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of Burkitt lymphoma. Burkitt lymphoma is a highly aggressive hematologic B-cell malignancy classically characterized by the overexpression of c-Myc. Due to the rapid proliferation rate of...
ASCO Supports NCI-Designated Cancer Centers’ Goal of Eliminating HPV-Related Cancers
ASCO HAS officially endorsed a statement by the 70 National Cancer Institute (NCI)-designated cancer centers calling for increased human papillomavirus (HPV) vaccination and screening to eliminate HPV-related cancers. The full uptake of the vaccine and screening could prevent 12,000 cervical...
New Fellows Begin 2018–2019 ASCO Health Policy Fellowship Program
TREVOR ROYCE, MS, MD, MPH, and Sheetal Kircher, MD, are the 2018–2019 ASCO Health Policy Fellows. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge, skills, and experience necessary to shape regulatory and legislative policies that directly ...
ASCO Resource Helps Patients Learn About Cancer Costs
HELP YOUR patients understand the financial impact of a cancer diagnosis with the ASCO Answers Managing the Cost of Cancer Care booklet. This booklet provides information about key financial categories for cancer care; an easy-to-understand explanation of health insurance coverage; information...
Today’s Breakthroughs Require Year-Round Support
PROMISING BREAKTHROUGHS in cancer care don’t just happen overnight; they result after years of hard work by the brightest minds in cancer research. Yet many are unaware of the vast resources necessary to fuel cutting-edge research projects. Increasing awareness around this issue is vital to...
Excerpt From the 2018 ASCO Presidential Address: ‘Delivering Discoveries: Expanding the Reach of Precision Medicine’
In my area of research, lung cancer, precision medicine is indeed transforming the treatment of this disease and has important implications for other cancers and for the future of our patients with cancer. Today’s achievement of being able to systematically identify genomic changes that can be...
Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
TESTICULAR CANCER is among the most common cancers in young men. The majority of patients are cured of their disease, but a newly published study shows many remain at risk for later complications from chemotherapy or other treatments. The study, published by Mohammad Abu Zaid, MD, Assistant...
A Humble Beginning Built on Commitment: The Life and Times of Lee S. Schwartzberg, MD, FACP
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed medical oncologist Lee S. Schwartzberg, MD, FACP, Executive Director at the West Cancer Center, Memphis. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer,...
Mariusz A. Wasik, MD, Joins Fox Chase as Chair of Pathology
MARIUSZ A. WASIK, MD, has been appointed Chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital. He will also serve as Associate Director of the Cancer Center, a position he assumed on July 2, 2018. As Chair of Pathology and a key member of Fox Chase’s leadership...
Carnegie Corporation Honors Antoni Ribas, MD
THE CARNEGIE CORPORATION of New York named University of California, Los Angeles (UCLA) Professor Antoni Ribas, MD, an honoree as part of its Great Immigrants Initiative, a program honoring a selected group of naturalized citizens who have made notable contributions to the progress of American...
